Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Interleukin-2 in Idiopathic Inflammatory Myopathy
NCT04062019Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Cytokines & Interferons
01
Overview
A Phase 2 trial of aldesleukin in idiopathic inflammatory myopathy (IIM), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
aldesleukin
03
Conditions
idiopathic inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT04062019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062019.